Selection of Products. WJPF shall decide which of the Products it wishes to distribute through the Designated Distributor in the PRC pursuant to the specific distribution agreements to be concluded in accordance with this Agreement and notify BRIDGETECH the Products in writing. The above-mentioned notice shall, in addition to the specific Product or Products, include the structure (either trading or profit-sharing structure) that WJPF and the Designated Distributor will adopt in distributing the Product.
Selection of Products. Subject to Section 3.3.3(b), with respect to the First Generation FocalGel Product or the First Generation Radiopharmaceutical Product or any of the first three Second Generation Products, if in the judgment of the Developing Party such product demonstrates efficacy, including without limitation demonstration of efficacy in a pig or other mutually agreed upon large animal model, the Developing Party shall use reasonable commercial efforts to conduct Product Development of the Product in question, at the Developing Party's sole expense. Focal shall be informed with respect to such Product Development. Focal agrees to provide reasonable mutually agreed technical support as reasonably necessary pursuant to the Research Plan and Budget; however, except as otherwise expressly agreed in writing, Focal shall have no obligation to perform pre-clinical studies other than those contained in the Research Plan and Budget or clinical studies or other portions of Product Development. It is understood during the term of this Agreement, the Developing Party may select a Product for Product Development at any time.
Selection of Products. The Customer acknowledges and agrees that:
Selection of Products. Development Candidates will become Products upon the filing of an IND for such Development Candidate, which filing will be made only after the JSC determines that such Development Candidate is suitable for clinical trials based on its preclinical profile and competitive and other commercial considerations.
Selection of Products. For each Development Candidate, during the Late Clinical Development Term and following review of the data from activities under the applicable Early Clinical Development Plan and Late Clinical Development Plan, the JSC will decide whether such Development Candidate should be selected as a Product for Commercialization pursuant to a Joint Commercialization Plan in accordance with the terms and conditions of this Agreement. If, following the review of data from activities under the applicable Early Clinical Development Plan and Late Clinical Development Plan, the JSC does not agree whether such Development Candidate is appropriate for selection as a Product, then a Party may exercise its Opt-Out Right with respect to such Development Candidate and associated Product in accordance with Section 3.2.
Selection of Products. (a) The Lead Products shall be the first Products that the Parties plan to Develop, Finalize, Manufacture and Commercialize pursuant to this Agreement.
Selection of Products. 31 4.5 Conduct of the Research Program.............................................................................. 32 4.6 Funding of the Research Program.............................................................................. 32 4.6.1 Pre-Development Expenses............................................................................... 32 4.6.2
Selection of Products. 34 4.5 Conduct of the Research Program .................................. 34 4.5.1 General ................................................... 34 4.5.2 Discovery Headcount and Development Leadership ............ 34 4.5.3 Performance of Clinical Work .............................. 34 4.5.4 Disagreement about Designation of a Compound as a Development Candidate ..................................... 35 4.6 Funding of the Research Program .................................. 36 4.6.1 Pre-Development Expenses .................................. 36 4.6.2
Selection of Products. 3.1.1 The Parties have agreed upon the Initial Collaboration Programs as of the Effective Date. At any time during the Program Selection Period, Regeneron shall have the option to nominate up to [***] additional Collaboration Programs, each focused on identifying Products which may include a combination of particular [***] for inclusion under this Agreement (such Collaboration Program, an “Additional Collaboration Program,” and such option, an “Additional Collaboration Program Option”).
Selection of Products. Epimmune shall have a period of [...***...] years after the Effective Date to designate up to [...***...] Products to be covered by the license granted in Section 2.1, during which time Epimmune may research and develop multiple product candidates using the Biological Material in the Field. Epimmune shall provide Valentis with written notice of the designation of each Product, which notice shall include a reasonably detailed description of such Product. After a product candidate is designated a Product hereunder up until the initiation of a Phase I Clinical Trial of such Product, Epimmune shall have the right to optimize such Product by substituting, deleting or adding [...***...] epitopes to such Product. Epimmune will notify Valentis in writing if it desires to so optimize any Product in this manner, and if
